Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00718146 | Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2008-2009 Formulation | PHASE2 | COMPLETED | 130 | — | — | Jun 1, 2008 | Sep 1, 2008 | Jan 17, 2014 | 2 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Age 16 to 60 years |
| Group 2 | EXPERIMENTAL | Age over 60 years |
| Name | Type | Description |
|---|---|---|
| Split virion, inactivated Influenza vaccine | BIOLOGICAL | 0.5 mL, Intramuscular (IM) |
Inclusion Criteria : * Aged 18 to 60 years or 61 years and older on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of child-bearing potential: avoid becoming pregnant (use of an effective method ...